期刊文献+

3/4肾切除大鼠心脏病变及三芪口服液的调控作用

下载PDF
导出
摘要 目的探讨3/4肾切除大鼠的心脏病变及三芪口服液干预的疗效。方法建立3/4肾切除大鼠并发早期心肾综合征模型,用三芪口服液治疗,并以缬沙坦作为对照组。检测血肌酐(Scr),观察心脏形态及病理变化,探讨三芪口服液的干预作用;结果模型组与空白组比较,血肌酐升高(P<0.01)、左心室/全心重(LVw/Hw)、LVw/体重(Bw)、Hw/Bw上升(P<0.01,P<0.05,P<0.05)。三芪组与模型组比较,血肌酐、LVw/Hw、LVw/Bw均较模型组减低(P<0.05,P<0.01,P<0.05),与缬沙坦组比较差异无统计学差异(P>0.05)。心肌苏木素-伊红(HE)、Masson染色方面,模型组出现心肌细胞肥大,排列不均匀,相同切片做Masson染色后,纤维排列疏松、紊乱,部分间质有蓝色胶原沉积;三芪组、缬沙坦组与模型组比较,心肌细胞肥大及排列不均匀明显改善,未见明显心肌间质胶原沉积。结论 3/4肾切除大鼠模型是早期心肾综合征的良好模型,三芪口服液可降低模型大鼠Scr水平,改善肾功能,并且能降低LVw/Hw、LVw/Bw,改善左心室重构及心肌纤维化。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2014年第13期3670-3672,共3页 Chinese Journal of Gerontology
基金 广东省中医药管理局资助(No.20131178)
  • 相关文献

参考文献5

  • 1孟华,郭军,翟雅莉,赵丽芳,李源,王晓明.替米沙坦联合丹参多酚酸盐治疗老年继发性慢性肾脏病的疗效[J].中国老年学杂志,2012,32(10):2140-2141. 被引量:11
  • 2侯凡凡,马志刚,梅长林,戎殳,黄颂敏,刘先蓉,袁伟杰,郭云珊,王莉,何强,王秀玲,桑晓红,栗霄立.中国五省市自治区慢性肾脏病患者心血管疾病的患病率调查[J].中华医学杂志,2005,85(7):458-463. 被引量:183
  • 3Ana Margarida Teixeira,Patrícia Garrido,Paulo Santos,Rui Alves,Belmiro Parada,Elísio Costa,Anabela Almeida,Edite Teixeira-Lemos,José Sereno,Rui Pinto,Luís Belo,Alice Santos-Silva,Frederico Teixeira,Flávio Reis.Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure[J].Renal Failure.2010(9)
  • 4P. Garrido,F. Reis,E. Costa,E. Teixeira-Lemos,B. Parada,R. Alves,N. Piloto,J. Sereno,A. Figueiredo,R. Pinto,L. Carvalho,P. Rocha-Pereira,L. Belo,A. Santos-Silva,F. Teixeira.Characterization of a Rat Model of Moderate Chronic Renal Failure—Focus on Hematological, Biochemical, and Cardio-Renal Profiles[J].Renal Failure.2009(9)
  • 5Claudio Ronco,Mikko Haapio,Andrew A. House,Nagesh Anavekar,Rinaldo Bellomo.Cardiorenal Syndrome[J]. Journal of the American College of Cardiology . 2008 (19)

二级参考文献21

  • 1王逸平,宣利江.中药现代化的示范性成果——丹参多酚酸盐及其注射用丹参多酚酸盐的研究与开发[J].中国科学院院刊,2005,20(5):377-380. 被引量:68
  • 2Hurley L, Kempe A, Crane LA, et al. Care of undocumented individuals with ESRD:a national survey of US nephrologists[ J ]. Am J Kidney Dis, 2009 ;53 (6) :940-9.
  • 3Zhang L,Zhang P, Wang F,et al. Prevalence and factors associated with CKD : a population study from Beijing [ J ]. Am J Kidney Dis, 2008 ; 51 : 373 -84.
  • 4侯凡凡.慢性肾脏病的心血管并发症[J].中华心血管病杂志,2004,32:16-16.
  • 5何长民 张训 见:何长民 张训主编.前言[A].见:何长民,张训主编.肾脏替代治疗学[C].上海:上海科学技术文献出版社,1999.2..
  • 6Locatelli F, Pozzoni P, Tentori F, et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant, 2003,18 Suppl 7:2-9.
  • 7Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol, 2002,13:745-753.
  • 8Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol, 2003,41:47-55.
  • 9Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int, 1995,47:186-192.
  • 10Sarnak MJ, Levey AS, Schoolwerth AC,et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation, 2003,108:2154-2169.

共引文献194

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部